Ariad: Shares Overvalued On Fundamentals

Healthcare Sector and Stocks Analysis from Seeking Alpha

Tue, 5 Feb 2013

By Poonam A. Arora : Ariad Pharmaceuticals ( ARIA ) is a biotechnology company that discovers, develops, and commercializes treatments for cancer. Last December, its lead drug Ponatinib was approved by the FDA for managing chronic myeloid leukemia ( CML ) and Philadelphia chromosome-positive acute ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Topics:

Related Videos

Will 'Knockout' Mice Make a Knockout Stock?

Thu, 28 Jan 2010

After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals ?

Content Partners

Site Directory Site Map Our Products

Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News

International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland

Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.